

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

### **VOLUNTARY ANNOUNCEMENT**

## **SUCCESSFUL COMPLETION OF THE FIRST TWO COMMERCIAL IMPLANTS WITH THE Trilogy™ Heart Valve System IN HONG KONG**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the successful completion of the first two commercial implants with the Trilogy™ Heart Valve System (the “**System**”), a licensed-in transcatheter aortic valve replacement (“**TAVR**”) product, in Hong Kong. The procedures were performed on May 12, 2023 at the Queen Elizabeth Hospital by Dr. Michael Kang-Yin Lee and his team. The System is CE-Mark approved and is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. As of the date of this announcement, the System is the first and only licensed transfemoral TAVR system globally for aortic regurgitation indication. The successful completion of the procedures marked the first commercial application of Trilogy™ in Asia and was a major accomplishment of the Group’s pipeline development.

Reference is made to the Company’s announcement dated January 14, 2022. The Group obtained an exclusive license from JenaValve Technology, Inc. of developing, manufacturing and commercializing the System in the Greater China region. In addition to the commercial implants in Hong Kong, the Group has completed the technology transfer of the System and is preparing to launch the registration clinical trial in the mainland China.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET Trilogy™ Heart Valve System SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board of Directors  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, May 15, 2023

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.*